Spero Therapeutics names Amy Rock chief regulatory and quality officer
SPRO•Spero Therapeutics appointed Amy Rock chief regulatory and quality officer. The company also named Dae Gon Ha senior vice president of corporate development and said Chief Operating Officer Timothy Keutzer will retire effective December 31, 2026.
1. Executive appointments
Spero Therapeutics appointed Amy Rock chief regulatory and quality officer. Rock previously served as senior vice president of regulatory sciences at Vir Biotechnology and has more than 25 years of biopharmaceutical experience. Dae Gon Ha joins as senior vice president of corporate development after leading strategy and business development at Fulcrum Therapeutics.
2. Planned retirement
Chief Operating Officer Timothy Keutzer will retire effective December 31, 2026, after 11 years of service. Other executive leadership team members will assume his responsibilities.
